CRDF|Cardiff Oncology Inc|Price:0.845|
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies for various cancers using PLK1 inhibition. Their lead drug candidate, Onvansertib, is in clinical trials for indications like RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and …